Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
New Lymphoma Therapy Helps Patients Live Longer
This retrospective cohort study of 79 Korean patients with relapsed or refractory diffuse large B-cell lymphoma evaluated tisagenlecleucel. …
A new study shows a specific immune therapy can shrink tumors and extend life for lymphoma patients who have run out of options.
Review of pediatric B-ALL CAR-T therapy identifies RAS mutation outcome predictor
New Test Predicts CAR-T Success in Kids
This narrative review synthesizes observational data from 86 pediatric patients with relapsed or refractory B-cell acute lymphoblastic leuke…
A new test can spot hidden genetic risks before a child starts powerful CAR-T cancer therapy.
Phase III trial compares tisagenlecleucel to standard transplant in relapsed aggressive B-cell NHL
Can a one-time cell therapy beat standard treatment for aggressive lymphoma?
This randomized, open-label, multicenter phase III trial enrolled 322 adults with aggressive B-cell NHL relapsed/refractory within 1 year of…
A major trial compares one-time CAR-T cell therapy against standard chemo and stem cell transplant for aggressive lymphoma that returns quic…